FDA authorizes booster doses for 12- to 15-year-olds, shortens interval for adults

A health worker administers a third dose of the Pfizer-BioNTech COVID-19 vaccine to an elderly resident at Ichilov medical center in Tel Aviv, Israel, on Monday, Aug. 2, 2021.

Enlarge / A health worker administers a third dose of the Pfizer-BioNTech COVID-19 vaccine to an elderly resident at Ichilov medical center in Tel Aviv, Israel, on Monday, Aug. 2, 2021. (credit: Getty | Bloomberg)

As the ultra-transmissible omicron coronavirus variant bears down on the US, the Food and Drug Administration on Monday announced a set of sweeping changes to the availability of Pfizer-BioNTech booster doses.

The regulator expanded access to third doses by authorizing their use for kids 12 to 15 years old. The agency also shortened the interval at which adults and children 12 and up can get a booster after their second dose—moving the time from six months to only five months. Last, the FDA made third doses available to immunocompromised children ages 5 to 11 who may not mount a strong response from only the first two doses.

The FDA's moves are motivated by omicron and backed by data from Israel, which has a booster program further along than that of the US. In fact, Israeli officials on Monday began offering fourth doses (second booster doses) of the Pfizer-BioNTech vaccine to people ages 60 and over in an effort to sustain high levels of protection in the population. The omicron variant, which is currently powering a vertical rise in cases in the US, has been found to thwart protection from only two vaccine doses, but it can still be defeated with booster doses.

Read 9 remaining paragraphs | Comments



source https://arstechnica.com/?p=1823148
Md Shuvo

Md Shuvo, known professionally as Shuved, is an Bangladeshi Musical Artist, Entrepreneur & YouTube Personality.

Post a Comment

Previous Post Next Post